D.E. Shaw & Co’s GT Biopharma GTBP Stock Holding History

D.E. Shaw & Co’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-57	Closed	-$129K	–	5691
2021 Q4	$129K	Sell	57 -111	-66%	-$415K	﹤0.01%	5004
2021 Q3	$848K	Buy	168 +144	+600%	+$1.08M	﹤0.01%	3734
2021 Q2	$275K	Buy	+24	New	+$249K	﹤0.01%	4319

Other funds holding GTBP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

D.E. Shaw & Co's GTBP Position: Q1 2022 in Review

D.E. Shaw & Co sold out of GT Biopharma (GTBP) in Q1 2022, closing a stake of 57 shares — an estimated $129K sold.

D.E. Shaw & Co first reported a position in GTBP in Q2 2021 and held it in 3 quarters. The position peaked at $848K in Q3 2021. 53 funds tracked by Wall St. Rank hold GTBP as of Q1 2022.

D.E. Shaw & Co reported no remaining GT Biopharma position as of Q1 2022 after selling out during the quarter.
D.E. Shaw & Co sold 57 GT Biopharma shares in Q1 2022, an estimated $129K.
D.E. Shaw & Co first reported a position in GT Biopharma in Q2 2021 and held it in 3 quarters.
D.E. Shaw & Co's GT Biopharma position peaked at $848K in Q3 2021.
53 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2022.

Based on D.E. Shaw & Co's 13F filing for Q1 2022, filed 16 May 2022.